Publications

BibTex format

@article{Syed:2012:10.18632/oncotarget.332,
author = {Syed, N},
doi = {10.18632/oncotarget.332},
journal = {Oncotarget},
pages = {78--83},
title = {Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer},
url = {http://dx.doi.org/10.18632/oncotarget.332},
volume = {3},
year = {2012}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The polo-like kinase PLK2 has recently been identified as a potential theranostic marker in the management of chemotherapy sensitive cancers. The methylation status of the PLK2 CpG island varies with sensitivity to paclitaxel and platinum in ovarian cancer cell lines. Importantly, extrapolation of these in vitro data to the clinical setting confirms that the methylation status of the PLK2 CpG island predicts outcomes in patients treated with carboplatin & paclitaxel chemotherapy. A second cell cycle regulator, p57Kip2, is also subject to epigenetic silencing in carboplatin resistance in vitro and in vivo, emphasising that cell cycle regulators are important determinants of sensitivity to chemotherapeutic agents and providing insights into the phenomenon of collateral drug sensitivity in oncology. Understanding the mechanistic basis and identification of robust biomarkers to predict collateral sensitivity may inform optimal use of chemotherapy in patients receiving multiple lines of treatment.
AU  - Syed,N
DO  - 10.18632/oncotarget.332
EP  - 83
PY  - 2012///
SN  - 1949-2553
SP  - 78
TI  - Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer
T2  - Oncotarget
UR  - http://dx.doi.org/10.18632/oncotarget.332
UR  - https://www.oncotarget.com/article/332/text/
UR  - http://hdl.handle.net/10044/1/82274
VL  - 3
ER  -

Download

DrNeloferSyed

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)